Why XENE fell 20.7% on Sep 17 2026: clinical safety pause
XENE-20.7%on Thu Sep 17 2026
Xenon Pharmaceuticals Inc was down 20.7% on the day at $45.00, ranked #1 on 61.2× its usual five-minute volume, when TapeRank recorded this drop at 16:11 ET during after hours.
WHAT THE ROW LOOKED LIKE
LAST45.00
DAY▼ 20.7%
5 MIN▼ 7.94%
5M RVOL61.2×
5M $VOL$2.0M
FLOAT*96.7M
RANK#1
SESSIONAFTER-HOURS
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
AI VERDICT
JUSTIFIEDCONFIDENCE5/5
XENE fell 8.6% after voluntarily pausing enrollment of new patients in ongoing depression studies because of neuropsychiatric adverse events. The FDA filing and completed enrollment are positive, but the unexpected safety-related pause is the more immediate market-moving development and reasonably explains the decline.
WHYAn 8.6% drop is proportionate to a precautionary clinical-study enrollment pause involving adverse events, despite the simultaneous NDA submission and progress updates.
ANALYZED 16:07 ET · 3 MIN AGO · OPENAI/GPT-5.6-LUNA
FILINGS · 24H BEFORE THE MOVE
- 16:05 ETXenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain ActiveBenzinga
- 16:05 ETXenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027Benzinga
- 16:02 ETXenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDABenzinga
SESSION LEVELS AT CAPTURE
VWAP57.01
HOD58.15
LOD45.12
OR HIGH—
OR LOW—
PREV CLOSE56.76
PM HIGH—
PM LOW—
GAP▲ 1.48%
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO